We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Boston Scientific Corporation | NYSE:BSX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 72.85 | 15 | 10:03:03 |
From May 2019 to May 2024
By Josh Beckerman
Pulmonx Corp., a medical device company that provides the Zephyr valve system for severe emphysema, disclosed plans for an initial public offering.
Pulmonx previously filed confidentially for an IPO. The Redwood City, Calif., company is seeking a Nasdaq Global Market listing under the symbol LUNG.
Boston Scientific Corp. owns 30% of Pulmonx. Last May, Pulmonx closed $65 million of equity financing led by Ally Bridge Group.
Pulmonx had 2019 revenue of $32.6 million, compared with $20 million in 2018.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 28, 2020 18:36 ET (23:36 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Boston Scientific Chart |
1 Month Boston Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
